Ulcerative Colitis

Antibe's development strategy is to improve existing drugs by incorporating immunomodulatory components into their molecular structure, generating new, fully patent-protectable chemical entities with predictable toxicity and effectiveness profiles.

This approach is underpinned by a unique biotechnology platform, enabling the efficient development of improved versions of a range of drugs presently on the market.

The Company's lead drug is a derivative of mesalamine (5-aminosalicylic acid).

Mr.

Daniel Legault, President and CEO of Antibe Therapeutics commented, "This award from AHFMR represents strong third party validation of ATB-429, and of our drug development program as a whole.

We look forward to initiating our clinical trials, which are designed to rapidly establish proof-of-concept of this product in humans.

We are pleased that the AHFMR has chosen to support this innovative drug development program." About AHFMR: AHFMR's Technology Commercialization (TC) program assists Alberta innovators with the transfer of new ideas and scientific findings into successful commercial health-related products and services.

Since 1985, the TC program has supported over 240 people and projects for over $20 million.

About Antibe: Antibe Therapeutics is a privately held, early stage drug development company with offices in Calgary and Toronto, and with affiliate laboratories in the USA, United King...

Read more...